Tivicay (dolutegravir) / ViiV Healthcare 
Welcome,         Profile    Billing    Logout  
 26 Diseases   58 Trials   58 Trials   4692 News 


«12...3031323334353637383940...6263»
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD), Vitekta (elvitegravir) / Japan Tobacco, Gilead
    Clinical, Journal:  The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients. (Pubmed Central) -  Jul 1, 2021   
    In conclusion, our results provide further data on changes of inflammatory marker levels, especially for the new INSTIs. Our data show that among INSTIs, EVG seems to have a worse impact on inflammation.
  • ||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
    Journal:  The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis. (Pubmed Central) -  Jun 30, 2021   
    Our modelling suggests that injectable cabotegravir-rilpivirine offers potential benefits; however, to be a cost-effective option, its introduction might need to be carefully targeted to individuals with HIV who might otherwise have suboptimal adherence to ART. As data accumulate from trials and implementation studies, such findings can be incorporated into the model to better inform on the full consequences of policy alternatives.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Clinical, Journal, Monotherapy:  Long-term follow-up of HIV-infected patients on dolutegravir monotherapy. (Pubmed Central) -  Jun 27, 2021   
    Not yet recruiting --> Recruiting Long-term follow-up showed a low risk of VF under dolutegravir monotherapy, in a selected population of patients with previous long-term virological suppression and low HIV reservoir.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    PK/PD data, Journal:  Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics. (Pubmed Central) -  Jun 26, 2021   
    This study showed a pharmacogenetic association between dolutegravir pharmacokinetics and variants in the ABCG2, UGT1A1 and NR1I2 genes, particularly when combined. Further research is warranted to confirm these associations in population-specific studies and to investigate their putative relationship with dolutegravir pharmacodynamics.
  • ||||||||||  Intelence (etravirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Antiretroviral concentrations in the presence and absence of valproic acid. (Pubmed Central) -  Jun 26, 2021   
    Valproic acid does not have a major effect on antiretrovirals other than dolutegravir. The mechanism of this unexpected drug-drug interaction may be the combination of protein displacement, reduced absorption and CYP3A4 induction.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Trial completion date, Trial primary completion date:  Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals (clinicaltrials.gov) -  Jun 25, 2021   
    P2,  N=72, Recruiting, 
    Nevertheless, further studies are necessary to assess the impact of polymorphic accessory INSTI DRMs on INSTI-based ART regimens. Trial completion date: Dec 2021 --> May 2022 | Trial primary completion date: Nov 2021 --> Apr 2022
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Preparation of the Key Dolutegravir Intermediate via MgBr-Promoted Cyclization. (Pubmed Central) -  Jun 24, 2021   
    Subsequent substitution by aminoacetaldehyde dimethyl acetal and methyl bromoacetate gave rise to the expected precursor for cyclization, which was promoted by MgBr to highly selectively convert into pyridinone diester. The key dolutegravir intermediate was finally prepared by the selective hydrolysis of the corresponding diester via LiOH.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Trial completion date, Trial initiation date, Trial primary completion date:  The Effect of Dolutegravir on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers (clinicaltrials.gov) -  Jun 24, 2021   
    P1,  N=16, Not yet recruiting, 
    The key dolutegravir intermediate was finally prepared by the selective hydrolysis of the corresponding diester via LiOH. Trial completion date: Aug 2021 --> Jan 2022 | Initiation date: Feb 2021 --> Oct 2021 | Trial primary completion date: Aug 2021 --> Jan 2022
  • ||||||||||  bictegravir (GS-9883) / Gilead
    Journal:  Targeting SARS-CoV-2: A Systematic Drug Repurposing Approach to Identify Promising Inhibitors Against 3C-like Proteinase and 2'-O-RiboseMethyltransferase. (Pubmed Central) -  Jun 22, 2021   
    From the virtual screening results, two drug molecules were selected for each drug target protein [Paritaprevir (ΔG= -9.8 kcal/mol) &Raltegravir (ΔG= -7.8 kcal/mol) for 3CLpro and Dolutegravir (ΔG= -9.4 kcal/mol) and Bictegravir (ΔG= -8.4 kcal/mol) for 2'-OMTase]. After the extensive computational analysis, we proposed that Raltegravir, Paritaprevir, Bictegravir and Dolutegravir are excellent lead candidates for these crucial proteins and they could become potential therapeutic drugs against SARS-CoV-2.
  • ||||||||||  bictegravir (GS-9883) / Gilead
    Journal:  HIV-1 Integrase Inhibitors that are active against Drug-Resistant Integrase Mutants. (Pubmed Central) -  Jun 22, 2021   
    Both DTG and BIC potently inhibit most INSTI-resistant IN mutants selected by the INSTIs raltegravir (RAL) and elvitegravir (EVG)...The new INSTI cabotegravir (CAB), which is in late-stage clinical trials, has been shown to select for novel resistant mutants in vitro Thus, it is important to develop new and improved INSTIs that are effective against all the known resistant mutants...Both were superior to DTG, as evidenced by the data obtained with the IN mutant T66I/L74M/E138K/S147G/Q148R/S230N, which was selected by CAB using an EVG-resistant lab strain. These results support the preclinical development of 4d and provide information that can be used in the design of additional INSTIs that will be effective against a broad spectrum of resistant mutants.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
    Clinical, Journal:  Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor. (Pubmed Central) -  Jun 22, 2021   
    Recent evidence showed a possible link of dolutegravir-based regimens with weight gain, and a relationship between raltegravir use and changes in adipose tissue density and metabolic abnormalities, with an increased cardiovascular risk, has been suggested. We describe a case where dolutegravir monotherapy led to a decrease in adipose tissue density.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  HPLC-MS identification of acid degradation products of dolutegravir. (Pubmed Central) -  Jun 22, 2021   
    During the fragmentation process of dolutegravir and its degradation products DP1 to DP3 a formal addition of oxygen resulting in the respective carboxylic acid fragments was detected. This could be evidenced based on high resolution masses of the fragments as well as the comparison of the MS/MS spectra of the fragments with the spectra of the carboxylic acids DP4 and DP5.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching from efavirenz to dolutegravir. (Pubmed Central) -  Jun 4, 2021   
    However, there was concern that DTG would lead to increased rates of immune reconstitution inflammatory syndrome (IRIS), especially in the setting of late presentation to care. Three cases at the University Teaching Hospital in Lusaka, Zambia highlight this concern, especially in persons living with HIV (PLWH), resulting in tuberculosis (TB) co-infection.
  • ||||||||||  NN1213 / Novo Nordisk, Tivicay (dolutegravir) / ViiV Healthcare
    Enrollment closed:  DGVTAF: Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection (clinicaltrials.gov) -  Jun 4, 2021   
    P4,  N=74, Active, not recruiting, 
    Three cases at the University Teaching Hospital in Lusaka, Zambia highlight this concern, especially in persons living with HIV (PLWH), resulting in tuberculosis (TB) co-infection. Recruiting --> Active, not recruiting
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    [VIRTUAL] A DIAGNOSIS THAT SHOULD NOT BE MISSED () -  Jun 2, 2021 - Abstract #ESPID2021ESPID_1508;    
    However, HIV way of transmission is not clear, as we see in this case. The hypothesis of a contaminated blood transfusion in Angola during a severe malaria crisis is possible.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
    [VIRTUAL] Surveillance Of Transmitted Drug Resistance Mutations And Hiv-1 Genetic Variants In Panama (Poster Hall) -  May 31, 2021 - Abstract #WMF2021WMF_5408;    
    A recombination analysis from the reconstruction of haplotypes is necessary to define the identity of the CRFs and URFs found, for which the complete genome will be required to be sequenced. Identifying which subtypes or recombinants historically predominate in a geographic region and monitoring whether the identity and proportion of new infections reflect a static or changing landscape will help decide appropriate interventions.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Effect of Dolutegravir and Sertraline on the Blood Brain Barrier (BBB). (Pubmed Central) -  May 28, 2021   
    Identifying which subtypes or recombinants historically predominate in a geographic region and monitoring whether the identity and proportion of new infections reflect a static or changing landscape will help decide appropriate interventions. No abstract available